About this trial
The role of dietary interventions in improving symptoms of multiple sclerosis (MS) is of high interest amongst patients and researchers, but data supporting this evidence are limited. Current evidence indicates that A higher Expanded Disability Status Scale (EDSS) score correlates with poor diet quality in patients with MS. Moreover, even though disease-modifying therapies (DMT) improve disease course and prognosis, MS patients report a lower quality of life (QoL) than people without illness. The Mediterranean diet (Med-Diet) is beneficial in preventing cardiovascular comorbidities, and outcomes of a decrease in inflammation processes are evident. Recent studies suggest that the Med-Diet might positively affect MS QoL, However, empirical evidence remains unclear, limiting the possibility of evidence-based nutritional recommendations. In the current study, we aim to investigate the effect of the Mediterranean diet on the quality of life of patients with MS.
Methods:
Randomized controlled trial among MS patients aged 18-70. The participants will be randomly assigned to two 1:1 ratio groups: The med-diet group and the control group (no intervention). The intervention will be carried out for six months with subsequent six-months follow-up.
Nine nutrition sessions will be delivered to the intervention group by an expert registered clinical dietitian. Data will be collected at baseline, three months, six months, and 12 months, including the following: Demographic, Anthropometric measurements, Blood tests of complete blood count, chemistry, levels of vitamins D, and B12, CRP, neurofilaments light chain (NfL), Grip strength, Biochemical analysis for fatty acid composition in membranes of red blood cells (RBC) and HPLC analysis of carotenoid concentration. Patients will complete questionnaires for multiple sclerosis quality of life-54 (MSQoL-54), Patient Health Questionnaire (PHQ-9), Fatigue Severity Scale Questionnaire (FSS) and will undergo clinical evaluation for expanded disability status scales (EDSS) and Symbol Digit Modalities Test (SDMT). Dietary analysis and Med-Diet adherence will be validated by the Israeli Mediterranean diet screener (I-MEDAS) and by Food diaries.
Calculated sample size: To achieve a mean difference of 10 points in the MSQoL-54 questionnaire and 80% power, a sample of 77 participants per group is needed. Considering a 5% drop-off, 81 participants per group are needed, and overall, 162 participants.
Expected results: this study will highlight the effect of the Med-Diet dietary pattern on MS quality of life, MS symptoms, and its underlying mechanism, to enable evidence-based nutritional recommendations for MS patients
Importance to Medicine: MS patients suffer from a decrease in QoL. Hence, physicians, researchers, and patients seek nutritional approaches that may improve their condition. If proven beneficial, The Med diet, a dietary approach that has been proven to reduce the risk for major comorbidities and that can be sustained throughout life, has the potential to improve the condition of MS patients in crucial lifestyle aspects.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Confirmed MS based on 2017 Mcdonald criteria, with stable medication regimen in the previous six months.
Disqualifiers
Pregnancy or lactating
People with a lack of judgment
Serum creatinine ≥2 mg/dL(177 μmol per liter) or more
Patients who had gastrointestinal problems that would prevent them from following any of the test diets
Trial design
Parallel
Treatments tested in this trial
Mediterranean Medical Nutrition Therapy (counselling)
BehavioralThe participants in the intervention group will receive dietary guidance on the Mediterranean diet during 9 sessions over six months. The sessions which will be held in groups of ten individuals. In-person group sessions will be held three times: at the first meeting, after three months, and after six months. During the remaining six sessions, 6 online video sessions (by the institutional telemedicine program) will be delivered and include 60 minutes of nutritional educational sessions with a registered dietitian once a month
Treatment groups
Trial outcomes
Primary outcomes
MS QOL score
As measured in MSQOL-54 questionnaire. score range 0-100. Higher score mean a better outcome.
Secondary outcomes
Disease Disability score
Decrease in Expanded disability status scale (EDSS) score. Range between 0-10. Higher score mean worse outcome
Chronic fatigue levels
Fatigue Severity Scale (FSS) questionnaire score. Range of score between 1-7. Higher score mean worse outcome.
Depression levels
As measured in PHQ-9 Questionnaire. Score range between: 0-27. Higher score mean worse outcome.
Carotenoid plasma concentration.
Other outcomes
Vitamin B12
As measured in blood plasma
Body Mass Index (BMI)
Measured in kg/m2
Muscle strength
As measured by JAMAR hand grip
Low density lipoprotein levels (LDL)
As measures in blood plasma
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Tel-Aviv Sourasky Medical Center
Lead sponsor
Ariel University
Collaborator